Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 303

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 303
---
25, 2024, Sullivan sent a revised draft of the Merger Agreement to Pearl Cohen, which included comments regarding the representations and warranties, post -closingboard of directors, and the proposed exchange ratio. The parties initially agreed to confirm the representations and warranties for both parties. Between August25, 2024 and September13, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated further the aforementioned terms of the Merger Agreement. On August29, 2024, Pearl Cohen sent the initial draft of the CVR Agreement to Sullivan. Between August29, 2024 and November4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated the terms of the CVR Agreement. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. The terms negotiated between the parties, among others, included the responsibilities of the rights agent, mechanics of the distribution, and term of the CVR Agreement. On September17, 2024, Sullivan sent the initial draft of the NLS Voting Agreement to Pearl Cohen. Between September17, 2024 and November4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated the terms of the NLS Voting Agreement. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. On September22, 2024, Pearl Cohen sent the initial draft of the Kadimastem Voting Agreement to Sullivan. Between September22, 2024 and November4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated the terms of the Kadimastem Voting Agreement. Regular meetings by phone call and video conference took place during this period, some of which included the parties’ respective legal counsel and financial advisors. On September23, 2024, Pearl Cohen sent a revised draft of the Merger Agreement to Sullivan, which included comments regarding the equity awards and warrants. The parties agreed to transfer all the Kadimastem equity awards to NLS, and between September23, 2024 and November4, 2024, Sullivan and Pearl Cohen exchanged drafts and negotiated further the equity awards provisions in the Merger Agreement. On September25, 2024, NLS, Kadimastem and Donohoe Advisors had a call to discuss the Nasdaq compliance of the combined company. On November4, 2024, the parties executed the Merger Agreement and the applicable ancillary documents, and